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Abstract 
Heavy training is associated with increased respiratory infection risk and antimicrobial 
proteins are important in defence against oral and respiratory tract infections. We examined 
the effect of 14 weeks of vitamin D3 supplementation (5000 IU/day) on the resting plasma 
cathelicidin concentration and the salivary secretion rates of secretory immunoglobulin A 
(SIgA), cathelicidin, lactoferrin and lysozyme in athletes during a winter training period. 
Blood and saliva were obtained at the start of the study from 39 healthy men who were 
randomly allocated to vitamin D3 supplement or placebo. Blood samples were also collected 
at the end of the study; saliva samples were collected after 7 and 14 weeks. Plasma total 
25(OH)D concentration increased by 130% in the vitamin D3 group  and decreased by 43% in 
the placebo group (both P=0.001). The percentage change of plasma cathelicidin 
concentration in the vitamin D3 group was higher than in the placebo group (P=0.025). Only 
in the vitamin D3 group, the saliva SIgA and cathelicidin secretion rates increased over time 
(both P=0.03). A daily 5000 IU vitamin D3 supplement has a beneficial effect in up-
regulating the expression of SIgA and cathelicidin in athletes during a winter training period 
which could improve resistance to respiratory infections.  
 
Introduction  
Vitamin D can be obtained either from dietary sources or the epidermal layer of the skin via 
exposure to sunlight. Two forms of vitamin D can be obtained from dietary sources: vitamin 
D3 (cholecalciferol) and vitamin D2 (ergocalciferol). While vitamin D3 is found in food from 
animal origin, such as cod-liver oil, salmon and egg yolk, vitamin D2 is present in some 
plants and fungi. The vitamin D3 production from ultraviolet-mediated conversion of 7-
dehydrocholesterol in the plasma membrane of skin cells provides 80-100 % of the body’s 
requirements (Lanteri et al., 2013). The endogenously synthesised vitamin D3 and diet-
derived D2 and D3 must first be hydroxylated in the liver into 25-hydroxy vitamin D 
(25(OH)D), the main storage form. In the second hydroxylation, 25(OH)D is converted to the 
biologically active form, 1,25-dihydroxy vitamin D, by 1-α-hydroxylase in the kidney or 
some cells in non-renal compartments, such as cells of the immune system including T cells, 
B cells, macrophages and dendritic cells (Aranow, 2011). 
It has recently been recognised that vitamin D is a vital mediator of innate immune responses, 
enhancing the antimicrobial properties of immune cells such as monocytes and macrophages 
(Bikle, 2009). Vitamin D is a key link between Toll-like receptor activation and antimicrobial 
responses in innate immunity. Following activation of the Toll-like receptor signalling 
cascade in the presence of microbes, vitamin D has a vital role in up-regulating the 
production of antimicrobial proteins (AMPs), such as cathelicidin and β-defensin (Liu et al., 
2006). The biologically active, 1,25-dihydroxy vitamin D, binds to vitamin D receptors and 
induces expression of vitamin D responsive genes to enhance the production of cathelicidin 
and β-defensin (Wang et al., 2004). These AMPs have a broad range of activities against 
microorganisms and may be involved in the direct inactivation of viruses through membrane 
destabilization (Kamen & Tangpricha, 2010). They are produced by epithelial cells and 
macrophages and in the lungs are secreted into the biofilm covering the inner surface of the 
airways, thereby creating a barrier that is chemically lethal to microbes. Recently, we 
demonstrated that vitamin D status influences the resting plasma cathelicidin concentration 
and salivary SIgA secretion rate in endurance athletes during a winter training period (He et 
al., 2013). The plasma cathelicidin concentration in athletes with high-level vitamin D status 
(plasma 25(OH)D >90 nmol/L) was significantly higher than in athletes with low-level 
vitamin D status (<33 nmol/L) and there was a positive correlation between the plasma 
25(OH)D and cathelicidin concentrations. In addition, the averaged SIgA secretion rate 
during the 4-month winter period in the individuals who had relatively high vitamin D status 
(plasma 25(OH)D >120 nmol/L) was significantly higher than in  groups having adequate, 
inadequate and deficient vitamin D status (adequate: 50–99.9 nmol/L; inadequate: 30–49.9 
nmol/L; deficient: <30 nmol/L) as previously established for bone health. 
Vitamin D insufficiency has been reported to be common in athletes in the United Kingdom 
(UK) especially when training in the winter months (Close et al., 2013; He et al., 2013; 
Morton et al., 2012). Two studies that assessed the vitamin D status of UK-based professional 
athletes (latitude 53N) reported that 62% of athletes (38/61) including professional rugby 
players, soccer players and jockeys had inadequate serum total 25(OH)D concentrations (< 
50 nmol/L) in the winter months (Close et al., 2013) and 65% of elite soccer players in the 
English Premier League (13/20) presented with serum total 25(OH)D concentrations <50 
nmol/L in December (Morton et al., 2012).In our previous study on a large student cohort of 
endurance athletes, we also found that 55% of endurance athletes (100/181) had serum total 
25(OH)D concentrations  <50 nmol/L at the end of the 4-month winter training period (He et 
al., 2013). Given that the high prevalence of insufficient vitamin D status in athletes in the 
UK during winter months, it seems probable that vitamin D supplementation could be 
desirable for athletes during this period to increase vitamin D concentrations to up-regulate 
the expression of AMPs and possibly reduce the risk of respiratory infections. 
The purpose of this study was to examine the effect of 14 weeks of vitamin D3 
supplementation (5000 IU/day) on the resting plasma cathelicidin concentration and the 
salivary concentrations and secretion rates of SIgA, cathelicidin, lactoferrin and lysozyme in 
a population of individuals engaged in regular sport training during a winter training period. 
 
Methods 
Participants  
Fifty healthy men aged 20.4 ± 1.9 years who were engaged in regular sports training (such as 
rugby, volleyball, swimming, triathlon, cycling and racquet sports) from Loughborough 
University, UK (latitude 53N) volunteered to participate in the study during November 2013 
and their self-reported training loads (determined by a pre-screening questionnaire) averaged 
11 ± 4 h/week (mean ± SD). Participants were required to complete a comprehensive health-
screening questionnaire prior to starting the study and had not taken any regular medication 
or antibiotics in the 3 months prior to the study. All participants were fully informed about 
the rationale for the study and of all experimental procedures to be undertaken. Participants 
provided written consent to participate in the study, which had earlier received the approval 
of Loughborough University ethical advisory committee. Participants were enrolled after 
having fulfilled all inclusion criteria, and presenting none of the exclusion criteria 
(determined by questionnaire). Participants could be included if they were currently healthy 
(with no health problems or infection symptoms within the previous 2 weeks), engaged in 
regular sports training at least 3 sessions and at least 3 h of total moderate/high-intensity 
training time per week and were between 18-35 years of age. Participants representing one or 
more of the following criteria were excluded from participation: smoking or use of any 
medication, suffering from or had a history of cardiac, hepatic, renal, pulmonary, 
neurological, gastrointestinal, haematological or psychiatric illness. Participants were not 
allowed to take any other supplements, other than a daily multivitamin tablet providing no 
more than the Recommended Dietary Allowances of essential vitamins. 
 
Study protocol 
Information about the study was given to the participants 1-2 weeks before their first visit to 
the laboratory. For the first visit to the laboratory, participants arrived in the morning at 
09:00-12:00 following a 3-h fast and their body mass and stature were recorded. Participants 
were required to abstain from any strenuous physical activity for 24 h before coming to the 
laboratory.  Participants sat quietly for 10 min and completed a health-screening 
questionnaire and inclusion/exclusion criteria questionnaire before signing an informed 
consent form and providing an unstimulated saliva sample by passive dribble into a pre-
weighed sterile collection tube for a timed period (usually 2 min; longer was allowed if the 
volume of saliva collected after 2 min was insufficient). After centrifugation for 2 min at 
5000 g to remove cells and insoluble matter, saliva samples were stored frozen at -20ºC prior 
to analysis. Subsequently, a resting venous blood sample (6 ml) was obtained by 
venepuncture from an antecubital forearm vein into a vacutainer tube (Becton Dickinson, 
Oxford, UK) containing K3EDTA and haematological analysis was immediately carried out 
(including haemoglobin, haematocrit and total and differential leukocyte counts) using an 
automated cell-counter (A
c.T™5diff haematology analyser, Beckman Coulter, High 
Wycombe, UK). Participants had to have haematology variables within the normal reference 
range to be included in the study. The remaining EDTA blood was centrifuged for 10 min at 
1500 g and 4C and the plasma stored at -20C prior to analysis.  
The participants were randomly allocated to an intervention (vitamin D3 supplement) group 
or placebo group for 14 weeks in a double-blind fashion. The vitamin D3 group received a 
daily supplement of 5000 IU of vitamin D3 in capsule form, whereas the placebo group 
received a visually identical cellulose placebo capsule (Bio-Tech Pharmacal, Arkansas, USA). 
Participants were given a 7-week supply of vitamin D3 or placebo capsules and attended the 
laboratory again after 7 weeks to get another 7-week supply of supplement. Participants were 
also asked to fill in a standard short form of International Physical Activity Questionnaire 
(IPAQ; http://www.ipaq.ki.se/downloads.htm) at weekly intervals, thus providing the 
quantitative information on training loads in metabolic equivalents (MET)-h/week (Craig et 
al., 2003).  
Participants attended the laboratory after 7 and 14 weeks following a 3-h fast and their body 
mass was recorded again. Participants were also required to abstain from any strenuous 
physical activity for 24 h before coming to the laboratory. Blood samples were collected 
again at the end of the study and unstimulated saliva samples were collected after 7 and 14 
weeks. A total of 39 participants completed the study and provided sufficient blood for 
routine haematology and vitamin D status analysis at the start and end of the study and 
sufficient saliva (1 mL) for analysis of AMPs on all 3 occasions. 
 
Plasma analysis 
Plasma samples were analysed for total 25(OH)D and cathelicidin concentrations. Total 
25(OH)D (the sum of the 25-hydroxy metabolites of D2 and D3) in EDTA plasma was 
determined after a maximum of 8 months in storage (with no previous freeze-thaw cycles) 
using a  high pressure liquid chromatography - tandem mass spectrometer (Waters Acuity, 
Manchester, UK) as described by Owens et al. (2014) and recommended by Fraser & Milan, 
(2013) and Wallace, Gibson, de la Hunty, Lamberg-Allardt, & Ashwell (2010). 
Measurements were performed in a laboratory meeting the performance target set by the 
Vitamin D External Quality Assessment Scheme Advisory Panel for 25(OH)D assays. 
EDTA plasma with 20X dilution was assayed in duplicate for cathelicidin concentration 
using a commercially available ELISA kit (Hycult Biotech, Uden, The Netherlands) 
according to the manufacturers’ instructions. The intra-assay CV was ±2.4% across a 
working range of 0.1–100 g/L. 
 
Saliva analysis  
Saliva samples were analysed in duplicate for the salivary AMPs. The saliva volume 
collected was estimated by weighing and the saliva flow rate was calculated. Saliva samples 
with 5X dilution were analysed for SIgA using an ELISA kit (Salimetrics, Philadelphia, 
USA). Salivary lactoferrin and lysozyme were analysed using commercially available ELISA 
kits (Calbiochem, USA and Biomedical Technologies, USA, respectively) with 500X dilution. 
Saliva samples were also assayed for cathelicidin concentration using a commercially 
available ELISA kit (Hycult Biotech, Uden, The Netherlands). Secretion rates for each of the 
salivary AMPs were calculated as the multiple of the saliva flow rate and AMP concentration. 
All saliva assays were carried out in duplicate. The intra-assay CVs for all the assays were <4% 
across a working range of 2.5-600 mg/L for SIgA, 1.6-100 g/L for lactoferrin, 0.78-50 g/L 
for lysozyme and 0.1–100 g/L for cathelicidin. 
 
Statistical analysis 
The Shapiro-Wilk test was used to determine if data sets were normally distributed. 
Anthropometric, self-reported training load (h/week), average IPAQ scores (MET-h/week) 
and haematological variables were compared between the vitamin D3 and placebo groups 
using unpaired t tests for normally distributed data or nonparametric Mann-Whitney U test 
for non-normally distributed data. Plasma total 25(OH)D and cathelicidin concentrations at 
the start and end of the study were assessed between the vitamin D3 and placebo groups using 
nonparametric Wilcoxon signed ranks test and Mann-Whitney U test. The percentage change 
of plasma cathelicidin concentration during the study period was also compared between two 
groups using nonparametric Mann-Whitney U test. The changes in the concentrations and 
secretion rates of salivary AMPs as well as the salivary flow rates over the 14 weeks of the 
study in the vitamin D3 and placebo groups were assessed by two-way ANOVA or 
nonparametric Friedman tests with post hoc Dunn’s test and Mann-Whitney U test. Data are 
presented as mean (±SD) for data sets that were normally distributed; for data sets that were 
not normally distributed, the median and interquartile range are shown. The accepted level of 
significance was P<0.05. Where appropriate, effect sizes were calculated using Cohen’s d 
(G*Power Version 3.1). 
 
Results 
Adherence to the study 
Thirty nine participants (vitamin D3: n=20; placebo: n=19) completed the study and provided 
sufficient blood for routine haematology and analysis of 25(OH)D and cathelicidin 
concentrations on 2 occasions and sufficient saliva for analysis of AMPs on all 3 occasions. 
Reasons for dropout were given as foreign travel (N=3), injury (N=6) or due to undisclosed 
reasons (N=2). 
 Baseline characteristics and physical activity levels 
There were no significant differences in baseline anthropometrics or haematological variables 
between the vitamin D3 and placebo groups (Table 1). Analysis of the IPAQ questionnaires 
indicated that the weekly training loads during the study period were relatively stable within 
the vitamin D3 and placebo groups. The training loads averaged over the study period were 
not significantly different between the vitamin D3 and placebo group (Table 1). Median 
(interquartile range) training loads were 69.0 (49.3-80.3) MET-h/week in the vitamin D3 
group which is equivalent to about 11.4 h of moderate-vigorous activity per week and 78.2 
(47.6-112.0) MET-h/week in the placebo group which is equivalent to about 12.9 h of 
moderate-vigorous activity per week.  
 
Plasma total 25(OH)D and cathelicidin concentrations 
The median plasma total 25(OH)D concentration increased from 54.5 to 125.5 nmol/L at 
week 14 in the vitamin D3 group (P=0.001, effect size=2.71) and decreased from 57.0 to 32.5 
nmol/L in the placebo group at 14 weeks (P=0.001, effect size=0.95) (Table 2). At the end of 
the study there was a significant difference between groups (P<0.001, effect size=4.05). 
Although the median plasma cathelicidin concentration increased in both groups (vitamin D3: 
29.5 to 34.0 ng/mL, P=0.003, effect size=0.27; placebo: 30.9 to 33.6 ng/mL, P=0.048, effect 
size=0.16; Wilcoxon signed ranks test) (Table 2), the percentage change of cathelicidin 
concentration in the vitamin D3 group was higher than in the placebo group (vitamin D3: 
15.0%; placebo: 5.4%, P=0.025, effect size=0.75; Mann-Whitney U test) (Figure 1).  
 
Salivary variables 
While the concentrations of all salivary AMPs were not significantly altered over time in both 
vitamin D3 and placebo groups, the salivary flow rates increased over time in the vitamin D3 
group (P=0.022, effect size=0.32) (Table 3). The resting SIgA and cathelicidin secretion rates 
increased over time in the vitamin D3 group (but not in the placebo group) (SIgA: 58.8, 87.2, 
70.5 g/min, P=0.026, effect size=0.32; cathelicidin: 0.076, 0.103, 0.090 ng/min, P=0.030, 
effect size=0.21; Friedman tests) (Figure 2a and 2b). Salivary lysozyme secretion rate 
increased over time in both groups (time, P=0.002; two-way ANOVA) but lactoferrin 
secretion rate was unaltered (Figure 2c and 2d).  
 
Discussion 
As expected, plasma total 25(OH)D concentration significantly increased in the vitamin D3 
group and significantly decreased in the placebo group. The salivary SIgA and cathelicidin 
secretion rates significantly increased over time in the vitamin D3 group but not in the 
placebo group. In addition, the percentage change of plasma cathelicidin concentration in the 
vitamin D3 group was significantly higher than in the placebo group although plasma 
cathelicidin concentration significantly increased in both groups.  
We demonstrated that in athletes following 14 weeks of vitamin D3 supplementation with 
5000 IU/day there was a significant increase in the plasma total 25(OH)D concentration from 
54.5 to 125.5 nmol/L. This increase in total 25(OH)D is similar to a previous randomised 
placebo-controlled trial of 5000 IU daily vitamin D3 supplementation, where plasma 
25(OH)D levels increased significantly from 29 to 103 nmol/L in the intervention group after 
8 weeks of supplementation (Close et al., 2013). During the winter months, 5000 IU of 
vitamin D3 supplement daily is a possible way for athletes to elevate 25(OH)D concentrations 
above a mean of 100 nmol/L which some authors suggest is the optimal concentration for a 
number of beneficial effects (Heaney, 2011; Zittermann, 2003). It was also observed that 
plasma total 25(OH)D concentration significantly decreased in the placebo group from 
November to February probably reflecting seasonal changes and time from last effective 
ultraviolet exposure. Several other studies that assessed the plasma 25 (OH)D concentrations 
of UK-based athletes have shown that there was no change or a significant decrease in the 
plasma 25(OH)D levels during the winter training period in athletes without vitamin D 
supplementation (Close et al., 2013; He et al., 2013; Owens et al., 2014). This is most likely 
due to insufficient ultraviolet radiation of appropriate wavelength (290-315 nm) between 
November and March in the UK to produce vitamin D in the skin (Webb & Holick, 1988). 
In the present study the resting salivary SIgA and cathelicidin secretion rates significantly 
increased over time in the vitamin D3 group. To our knowledge, this is the first report to show 
a significant increase in the resting salivary SIgA secretion rates after a period of vitamin D3 
supplementation. The reasons for this are still unclear, but could be related to the elevated 
salivary flow rates after vitamin D3 supplementation. We report that the salivary flow rates 
significantly increased over time in the vitamin D3 group. Several animal studies have 
demonstrated that vitamin D receptors are present in the parotid, submandibular and 
sublingual salivary glands which suggest a possible role for vitamin D in regulation of 
salivary secretion. This is supported by the finding that salivary flow rates were stimulated 
after treatment with vitamin D3 in vitamin D-deficient rats (Peterfy et al., 1988; Stumpf, 
2008). Although the influence of vitamin D on salivary flow rate has not yet been 
demonstrated in humans, the finding that there was a significant positive correlation between 
plasma total 25(OH)D concentration and salivary flow rate in the endurance athlete cohort 
(N=225) (unpublished data in our previous study (He et al., 2013), r=0.196, P=0.003; Pearson 
correlation test) might lend some support to this suggestion.  
We also found that salivary cathelicidin secretion rates only significantly increased in the 
participants with vitamin D3 supplementation. Human cathelicidin is expressed in neutrophils, 
epithelial cells and salivary glands and can be detected in whole saliva (Davison et al., 2009; 
Murakami et al., 2002). The elevated salivary cathelicidin secretion rates might be due to the 
influence of 25(OH)D in the human oral epithelial cells. Human oral epithelial cells which 
express vitamin D receptors and 1-α-hydroxylase have the enzymatic machinery to convert 
25(OH)D to 1,25-dihydroxy vitamin D and it has been demonstrated that 25(OH)D can 
induce expression of the vitamin D responsive genes to enhance the production of 
cathelicidin by binding to vitamin D receptors  in dose-related manner in human oral 
keratinocytes (Wang et al., 2013). 
Our results indicate that 5000 IU of vitamin D3 supplement daily could have a beneficial 
effect in up-regulating plasma cathelicidin. We found that the percentage change of 
cathelicidin concentration in the vitamin D3 group was significantly higher than in the 
placebo group, although plasma cathelicidin concentration significantly increased in both 
groups from November to March. The reason for the increase of plasma cathelicidin 
concentration in the placebo group is unclear, but could be related to the likely higher 
respiratory infection incidence over the winter months as cathelicidin production is increased 
following pathogen exposure and Toll-like receptor activation (Bucki et al., 2010). Moreover, 
there was a similar result in another vitamin D3 supplement study in which 25 healthy 
participants with plasma 25(OH)D concentration less than 80 nmol/L ingested 50,000 IU 
vitamin D3 every other day, for 5 days, and a statistically significant increase of circulating 
cathelicidin concentration was only found in participants with 25(OH)D levels increasing 
more than 80 nmol/L after the vitamin D3 treatment (Bhan et al., 2011).  In our study, we also 
found a significant increase of plasma cathelicidin concentration in the vitamin D3 group 
although there were only 5 participants with 25(OH)D levels increasing more than 80 nmol/L 
after supplementation. It has been reported that patients with the lowest circulating 
concentrations of cathelicidin undergoing dialysis are at a greater than two-fold increased risk 
of death from infectious causes (Gombart et al., 2009). Given the observed associations of 
circulating cathelicidin concentrations and infection-associated mortality in human studies, a 
high dose of vitamin D3 supplementation might be clinically useful in the populations that 
may be more at risk of infection due to occupational or lifestyle stress (e.g. athletes and 
military personnel). 
Recently, it has been suggested that several salivary AMPs, such as SIgA and cathelicidin, 
might be associated with the incidence of upper respiratory tract infection. Previous studies 
have shown an inverse relationship between SIgA values and upper respiratory tract infection 
prevalence and low SIgA values have been reported to be associated with increased incidence 
of upper respiratory tract infection in athletes (Fahlman & Engels, 2005; Gleeson et al., 1999, 
2012; Neville et al., 2008). A one-year follow-up study has reported that the number of upper 
respiratory tract infection episodes was negatively correlated with salivary cathelicidin levels 
(Usui et al., 2012). Further studies are still needed to establish if the enhancement of salivary 
SIgA and cathelicidin secretion after vitamin D supplementation could reduce the risk of 
upper respiratory tract infection in athletes. 
In conclusion, 5000 IU of vitamin D3 supplementation daily appears to have a beneficial 
effect in up-regulating the expression of SIgA and cathelicidin in athletes during a winter 
training period. Vitamin D supplementation, therefore, could have a positive effect on 
immune function and lead to decreased incidence of respiratory infections. Further research 
in a substantially larger athlete cohort is needed to determine this possibility. 
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Figure legends 
Figure 1. The percentage change of plasma cathelicidin concentration after the 14-week 
intervention period in the vitamin D3 supplement and placebo groups. Data are median and 
interquartile range. * Significant difference between groups (P=0.025; Mann-Whitney U test). 
 
Figure 2. Changes in salivary secretion rates after 7 and 14 weeks of the intervention period 
in the vitamin D3 supplement and placebo groups for (A) SIgA, (B) cathelicidin, (C) 
lysozyme and (D) lactoferrin. Data are shown as the mean ± SD (lysozyme) or the median 
and interquartile range (SIgA, cathelicidin and lactoferrin) as appropriate. The location of 
significant differences from week 0 within the vitamin D3 supplemented group only is 
indicated as follows: * P<0.05; † P=0.05 (Dunn’s post hoc test applied when Friedman test 
P<0.05). Significant difference from week 0 in both groups is indicated as follows: # P<0.05. 
 
 
 
Table 1. Anthropometric, training and haematological variables in the vitamin D3 and placebo groups at baseline and their training 
loads determined by IPAQ during the intervention period 
 
Vitamin D3 (n=20) Placebo (n=19) P 
Age (years) 20.1 ± 1.7 21.0 ± 2.3 0.168 
Stature (cm) 181.9 ± 6.9 182.2 ± 8.0 0.907 
Body mass (kg) 80.8 ± 13.1 80.0 ± 11.2 0.849 
BMI (kg/m
2
) 24.3 ± 3.1 24.1 ± 2.6 0.769 
Previous training load (h/week) 10.1 ± 4.0 11.1 ± 4.8 0.503 
IPAQ (MET-h/week) 69.0 (49.3-80.3) 78.2 (47.6-112.0) 0.374 
RBC count (x10
12
/L) 4.8 ± 0.3 4.9 ± 0.3 0.231 
Haematocrit (%) 44.1 ± 1.9 43.8 ± 2.5 0.687 
Haemoglobin (g/L) 148 ± 7 146 ± 7 0.546 
Leukocyte count (x10
9
/L) 5.5 ± 1.4 5.7 ± 1.2 0.707 
Data are shown as the mean ± SD or the median and interquartile range as appropriate. P values are from unpaired t tests apart from IPAQ 
training load where the Mann-Whitney U test for nonparametric data was used. 
 
 
 
 
  
Table 2. Plasma total 25(OH)D and cathelicidin concentrations in the vitamin D3 and placebo groups before and after the 14-week 
intervention period 
  
Pre Post P 
Total 25(OH)D 
(nmol/L) 
 
Vitamin D3 54.5 (43.2-71.0) 125.5 (96.8-149.5) *  0.001 
Placebo 57.0 (38.7-71.0) 32.5 (26.7-49.3) 0.001 
Cathelicidin (g/L) 
 
Vitamin D3 29.5 (26.6-32.3) 34.0 (30.0-38.3) 0.003 
Placebo 30.9 (27.7-36.6) 33.6 (28.4-38.1) 0.048 
Data are shown as the median and interquartile range for nonparametric Wilcoxon signed ranks test. Significant difference between groups:  
* P < 0.001 based on Mann-Whitney U test. 
 
  
 Table 3. Salivary flow rate and AMPs concentration in the vitamin D3 and placebo groups before and after 7 and 14 weeks of the 
intervention 
 
  
Week 0 Week 7 Week 14 P 
Saliva flow rate (L/min) 
Vitamin D3 317 (181-420)     462 (254-642) *    358 (274-640) * 0.022 
Placebo 260 (192-496) 331 (242-540) 352 (251-532) 0.143 
SIgA concentration (mg/L) 
Vitamin D3 183.8 (142.0-221.8) 170.3 (121.3-235.8) 171.1 (145.6-217.2) 0.861 
Placebo 181.3 (130.4-227.0) 141.4 (120.0-249.9) 171.9 (105.5-245.0) 0.211 
Lactoferrin concentration (g/L) 
Vitamin D3 4715 (2875-5861) 5358 (2995-7596) 4485 (2342-6810) 0.350 
Placebo 4274 (1483-5450) 3772 (1763-5087) 5874 (1235-7550) 0.692 
Lysozyme concentration (g/L) 
Vitamin D3 2472 ± 2515 2986 ± 2907 2397 ± 1644 
time*group, 0.460 
Placebo 3367 ± 3135 3205 ± 2500 3018 ± 2389 
Cathelicidin concentration (g/L) 
Vitamin D3 0.22 (0.09-0.53) 0.32 (0.13-0.45) 0.23 (0.09-0.45) 0.463 
Placebo 0.25 (0.05-0.94) 0.16 (0.07-0.37) 0.20 (0.07-0.28) 0.065 
Data are shown as the mean ± SD for two-way ANOVA or the median and interquartile range for nonparametric Friedman test with post hoc 
Dunn’s test. The location of significant differences from week 0 within the group is indicated as follows: * P<0.05 (Dunn’s post hoc test applied 
when Friedman test P<0.05). 
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